METXF (ME Therapeutics Holding) Float Percentage Of Total Shares Outstanding: 0.00% (As of Aug. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

METXF ME Therapeutics Holding Inc METXF
14 GF Score
Price $3.25
! 1 Warning Sign
View Full Analysis

What is ME Therapeutics Holding Float Percentage Of Total Shares Outstanding?

ME Therapeutics Holding METXF 14 Float Percentage Of Total Shares Outstanding is 0.00% as of Aug. 26, 2026. GuruFocus rates METXF with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, ME Therapeutics Holding's float shares is 0.00 Mil. ME Therapeutics Holding's total shares outstanding is 30.05 Mil. ME Therapeutics Holding's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, ME Therapeutics Holding's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, ME Therapeutics Holding's Institutional Ownership is 0.00%.

METXF
14GF Score
ME Therapeutics Holding Inc METXF
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ME Therapeutics Holding Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

ME Therapeutics Holding's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/30.05
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 0.00% mean?
ME Therapeutics Holding (METXF) has a Float Percentage Of Total Shares Outstanding of 0.00% as of Aug. 26, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on ME Therapeutics Holding and its competitors.
Is ME Therapeutics Holding's Float Percentage Of Total Shares Outstanding too high?
ME Therapeutics Holding's current Float Percentage Of Total Shares Outstanding is 0.00%. Overall, ME Therapeutics Holding has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does ME Therapeutics Holding's Float Percentage Of Total Shares Outstanding compare to VRTX and REGN?
ME Therapeutics Holding's Float Percentage Of Total Shares Outstanding of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on ME Therapeutics Holding and its competitors. ME Therapeutics Holding's current Float Percentage Of Total Shares Outstanding is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ME Therapeutics Holding stock overvalued right now?
ME Therapeutics Holding (METXF) has a current Float Percentage Of Total Shares Outstanding of 0.00%. The current Float Percentage Of Total Shares Outstanding is 0.00%. ME Therapeutics Holding's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For ME Therapeutics Holding (METXF), the current Float Percentage Of Total Shares Outstanding is 0.00% as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ME Therapeutics Holding Business Description

Other Exchanges METX:Canada
Address 2665 East Mall, Room 249, Vancouver, BC, CAN, V6T 1Z4
ME Therapeutics Holding Inc is a preclinical stage biotechnology company working on cancer-fighting drugs in the field of Immuno Oncology, developing next-generation therapeutics targeting immune suppression in cancer. It is developing novel drugs that target myeloid cells to directly treat cancer and enhance the benefits of current Immuno Oncology drugs, such as checkpoint inhibitors in currently untreatable cancers. Immuno Oncology is a new area of cancer research that has been successful in treating previously untreatable cancers by targeting the immune system rather than the cancer directly, allowing a single drug to be used for multiple cancer types with mostly manageable side effects.
14GF Score

Get the complete analysis for METXF

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.25
Price